By Fineline Cube 
Shenzhen-based LTZ Therapeutics has reportedly raised USD 40 million in a Series A+ financing round led by Wanwu Growth Venture Capital. The round also saw participation from Lanchi Ventures, 5Y Capital, Unicorn Capital Partners, the Institute for Follicular Lymphoma Innovation, and returning investors Lapam Capital and GL Ventures. The proceeds will be used to advance the Phase I clinical trial of its first drug candidate, LTZ-301, and to submit an Investigational New Drug (IND) application for its second candidate, LTZ-232, targeting pan-tumor indications.
Company Background and Technology
LTZ Therapeutics, founded in 2022, is focused on addressing unmet clinical needs in cancer and autoimmune diseases. The company is developing novel immunotherapies based on its proprietary “myeloid cell adapter” technology platform. These therapies aim to enhance the phagocytic function of macrophages and monocytes across different polarization states, offering broad-spectrum immunotherapy solutions. Since its inception, LTZ Therapeutics has raised a total of USD 90 million.-Fineline Info & Tech